Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / American Depositary Shares, each representing one ordinary share
-
Shares outstanding
-
40.3M
-
Number of holders
-
19
-
Total 13F shares, excl. options
-
9.69M
-
Shares change
-
-235K
-
Total reported value, excl. options
-
$10.7M
-
Value change
-
-$279K
-
Number of buys
-
5
-
Number of sells
-
-4
-
Price
-
$1.19
Significant Holders of Barinthus Biotherapeutics plc. - American Depositary Shares, each representing one ordinary share (BRNS) as of Q3 2024
20 filings reported holding BRNS - Barinthus Biotherapeutics plc. - American Depositary Shares, each representing one ordinary share as of Q3 2024.
Barinthus Biotherapeutics plc. - American Depositary Shares, each representing one ordinary share (BRNS) has 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.69M shares
of 40.3M outstanding shares and own 24.04% of the company stock.
Largest 10 shareholders include M&G PLC (5.2M shares), Alphabet Inc. (1.51M shares), HSG Holding Ltd (1.42M shares), DC Funds, LP (642K shares), BlueCrest Capital Management Ltd (543K shares), Johns Hopkins University (122K shares), Baird Financial Group, Inc. (92.5K shares), RENAISSANCE TECHNOLOGIES LLC (27.9K shares), CITADEL ADVISORS LLC (27.7K shares), and Ipswich Investment Management Co., Inc. (22.6K shares).
This table shows the top 19 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.